Evidence map›Paper›PMID 34237284›Full record

ArticleCell reports2021

Resistance of SARS-CoV-2 variants to neutralization by antibodies induced in convalescent patients with COVID-19.

Yu Kaku, Takeo Kuwata, Hasan Md Zahid, Takao Hashiguchi, Takeshi Noda, Noriko Kuramoto, Shashwata Biswas, Kaho Matsumoto, Mikiko Shimizu, Yoko Kawanami and 19 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell reports, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 14 papers.

0numbers the graph read from it
0cells of the map it votes in
14citing papers in PubMed
2.0field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

14 citing papers in PubMed, 30 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. COVID-19 challenges and its therapeutics.Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 2021
    Review
  13. Article
  14. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

29 authors at 5 institutions in 1 country.

Yu KakuDivision of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Takeo KuwataDivision of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan. Electronic address: tkuwata@kumamoto-u.ac.jp.
Hasan Md ZahidDivision of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Takao HashiguchiLabolatory of Medical Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan; Department of Virology, Faculty of Medicine, Kyushu University, Fukuoka 812-8582, Japan.
Takeshi NodaLaboratory of Ultrastructural Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan; CREST, Japan Science and Technology Agency, Kawaguchi, Japan.
Noriko KuramotoDivision of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Shashwata BiswasDivision of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Kaho MatsumotoDivision of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Mikiko ShimizuDivision of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Yoko KawanamiDivision of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Kazuya ShimuraLaboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
Chiho OnishiLaboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
Yukiko MuramotoLaboratory of Ultrastructural Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
Tateki SuzukiDepartment of Virology, Faculty of Medicine, Kyushu University, Fukuoka 812-8582, Japan.
Jiei SasakiDepartment of Virology, Faculty of Medicine, Kyushu University, Fukuoka 812-8582, Japan.
Yoji NagasakiDivision of Infectious Diseases, Clinical Research Institute, National Hospitalization Organization, Kyushu Medical Center, Fukuoka, Japan.
Rumi MinamiInternal Medicine, Clinical Research Institute, National Hospital Organization, Kyushu Medical Center, Fukuoka, Japan.
Chihiro MotozonoDivision of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Mako ToyodaDivision of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Hiroshi TakahashiDepartment of Respiratory Medicine, Kumamoto City Hospital, Kumamoto 862-8505, Japan.
Hiroto KishiDepartment of Respiratory Medicine, Kumamoto City Hospital, Kumamoto 862-8505, Japan.
Kazuhiko FujiiDepartment of Respiratory Medicine, Kumamoto City Hospital, Kumamoto 862-8505, Japan.
Tsuneyuki TatsukeFaculty of Advanced Science and Technology, Kumamoto University, Kumamoto 860-8555, Japan.
Terumasa IkedaDivision of Molecular Virology and Genetics, Joint Research Center for Human Retrovirus Infection, Kumamoto University, Kumamoto 860-0811, Japan.
Yosuke MaedaDepartment of Microbiology, Faculty of Life Sciences, Kumamoto University, Kumamoto 860-8556, Japan.
Takamasa UenoDivision of Infection and immunity, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan.
Yoshio KoyanagiLaboratory of Systems Virology, Institute for Frontier Life and Medical Sciences, Kyoto University, Kyoto 606-8507, Japan.
Hajime IwagoeDepartment of Infectious Disease, Kumamoto City Hospital, Kumamoto 862-8505, Japan.
Shuzo MatsushitaDivision of Clinical Retrovirology, Joint Research Center for Human Retrovirus infection, Kumamoto University, Kumamoto 860-0811, Japan. Electronic address: shuzo@kumamoto-u.ac.jp.
Kumamoto University · JPKyoto University · JPKumamoto City Hospital · JPKyushu University · JPNational Kyushu Medical Center · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Administration of convalescent plasma or neutralizing monoclonal antibodies (mAbs) is a potent therapeutic option for coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. However, SARS-CoV-2 variants with mutations in the spike protein have emerged in many countries. To evaluate the efficacy of neutralizing antibodies induced in convalescent patients against emerging variants, we isolate anti-spike mAbs from two convalescent COVID-19 patients infected with prototypic SARS-CoV-2 by single-cell sorting of immunoglobulin-G-positive (IgG

Indexed as

Antibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralCell LineCOVID-19COVID-19 SerotherapyHEK293 CellsHumansImmunization, PassiveMaleMutationNeutralization TestsProtein DomainsSARS-CoV-2Spike Glycoprotein, CoronavirusAntibodies, MonoclonalAntibodies, NeutralizingAntibodies, ViralSpike Glycoprotein, Coronavirusspike protein, SARS-CoV-2COVID-19mAbneutralizing antibodySARS-CoV-2variant

Identifiers

PMID34237284
PMCPMC8226103
OpenAlexW3174602360

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.